Regular articlePeripherin is not a contributing factor to motor neuron disease in a mouse model of amyotrophic lateral sclerosis caused by mutant superoxide dismutase
Introduction
Amyotrophic lateral sclerosis (ALS) is a late-onset neurological disease characterized by the selective degeneration of upper and lower motor neurons leading ultimately to paralysis and death due to respiratory failure. ALS occurs in both sporadic (90% of cases) and familial forms, which are clinically and pathologically similar. Missense mutations in the gene encoding the free radical-scavenging metalloenzyme Cu/Zn superoxide dismutase 1 (SOD1) are responsible for approximately 20% of familial ALS (fALS) cases (Rosen et al., 1993). To date, over 90 mutations have been discovered spanning all exons of the SOD1 gene. Transgenic mice expressing various SOD1 mutants develop ALS-like phenotypes through a gain of unknown toxic properties Gurney et al 1994, Wong et al 1995, Ripps et al 1995, Tu et al 1996, Bruijn et al 1997, Bruijn et al 1998.
Peripherin is a type III neuronal intermediate filament (IF) protein of 57 kDa expressed predominantly in the peripheral nervous system. It is also detected at low levels in defined populations of central nervous system neurons, mostly in those extending to the periphery (Parysek and Goldman, 1988; Brody et al 1989, Escurat et al 1990, Gorham et al 1990. Because of its increased expression during development and following nerve injury, peripherin is believed to play a role in nerve elongation Escurat et al 1990, Gorham et al 1990, Wong and Oblinger 1990. However, the extent to which peripherin exerts its axonal growth function during development remains unclear since peripherin null mice do not show any defect in the development of large myelinated peripheral sensory and motor axons (Larivière et al., 2002). There is also evidence for an involvement of peripherin in the neuronal response to inflammation. Inflammatory cytokines, such as interleukin-6 (IL-6) and leukemia inhibitory factor (LIF), can upregulate peripherin expression through the activation of the JAK/STAT signaling pathway Djabali et al 1993, Sterneck et al 1996, Lecomte et al 1998. Also, we recently showed that peripherin expression can be induced in the brain following stab injuries and cerebral ischemia, two conditions associated with neuronal inflammation (Beaulieu et al., 2002).
Many observations have suggested a possible involvement of peripherin in the pathology of ALS. A pathological hallmark of human sporadic and fALS as well as of transgenic mice expressing ALS-linked SOD1 mutants is the presence of inclusion bodies containing peripherin, along with neurofilament (NF) proteins in the perikaryon and axon of degenerating motor neurons (reviewed in Chou 1995, Tu et al 1996; Morisson et al., 1998; Corbo and Hays 1992, Migheli et al 1993, Wong et al 2000. Moreover, overexpression of a peripherin transgene in mice resulted during aging in the selective degeneration of ventral root motor axons associated with the development of ALS-like IF inclusions in spinal motor neurons (Beaulieu et al., 1999). Finally, overexpression of peripherin in cultured embryonic neurons causes apoptotic death in synergy with tumor necrosis factor-α (TNF-α) (Robertson et al., 2001).
To further clarify the potential involvement of peripherin in ALS caused by SOD1 mutations, we generated SOD1G37R mice that either overexpress a mouse peripherin transgene or lack the endogenous peripherin gene. We then evaluated whether these changes in peripherin gene expression affected the development of the motor neuron pathology.
Section snippets
Transgenic mice
SOD1G37R (line 29) transgenic mice expressing the glycine 37 to arginine mutant form of human SOD1 (hSOD1) (Wong et al., 1995) were a gift of Drs. P. Wong and D. Price from John Hopkins University (Baltimore, MD). Peripherin knockout mice (Per−/− mice) (Larivière et al., 2002) and transgenic mice overexpressing wild-type mouse peripherin under the control of its own promotor (Per mice) (Beaulieu et al., 1999) were described previously.
Peripherin knockout mice expressing mutant hSOD1
Motor neurons in SOD1G37R mice develop peripherin accumulations without increase in mRNA levels
One of the pathological hallmarks of human ALS and of transgenic mutant SOD1 mice is the presence of inclusion bodies containing intermediate filaments in the perikaryon and axon of degenerating motor neurons (reviewed in Chou 1995, Tu et al 1996; Morisson et al., 1998; Beaulieu et al., 1999). We first investigated whether peripherin was present in those inclusions bodies in SOD1G37R mice. As shown in Fig. 1, the SOD1G37R mice exhibit enhanced immunohistochemical staining of motor neurons with
Discussion
To address the potential contribution of peripherin to pathogenesis in mice expressing mutant SOD1, we first analyzed the expression of peripherin in SOD1G37R mice by immunostaining, RT-PCR, and in situ hybridization. Our results showed an enhanced peripherin immunodetection in motor neurons of SOD1G37R mice. These mice also exhibited peripherin-positive axonal aggregates. However, this enhanced peripherin immunostaining was not a consequence of an upregulation of peripherin mRNA as revealed by
Acknowledgements
The technical help of Pascale Hince and Margaret Attiwell is gratefully acknowledged. We also thank Dr. Serge Rivest and Nathalie Laflamme for the in situ hybridization assays. This work was supported by the National Institute of Neurological Disorders and Stroke (NIH Grant 5 R01 NS41583-02). R.C.L. is a recipient of a FRSQ-FCAR-Health studentship. M.D.N. was a recipient of a KM Hunter-CIHR Ph.D. Scholarship and is currently supported by a Human Frontier Science Program Long-Term Fellowship.
References (36)
- et al.
Induction of peripherin inclusions in brain neurons following mechanical injury and focal cerebral ischemia
Brain Res.
(2002) - et al.
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions
Neuron
(1997) - et al.
The expression of the neuronal intermediate filament protein peripherin in the rat embryo
Brain Res. Dev. Brain Res.
(1990) - et al.
Cytosqueletal abnormalities in amyotrophic lateral sclerosisbeneficial or detrimental effects?
J. Neurol. Sci.
(2000) - et al.
The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction
Neuroscience
(1999) - et al.
Increased microglial activation and protein nitration in white matter of the ageing monkey
Neurobiol. Aging
(1999) - et al.
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria
Neuron
(1995) - et al.
Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments
Exp. Neurol.
(1997) - et al.
Late onset death of motor neurons in mice overexpressing wild-type peripherin
J. Cell Biol.
(1999) - et al.
Selective distribution of the 57kDa neural intermediate filament protein in the rat CNS
J. Neurosci.
(1989)
Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1
Science
Pathology of motor system disorder
Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease
J. Neuropathol. Exp. Neurol.
Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase
Proc. Natl. Acad. Sci. USA
Peripherin expression in hippocampal neurons induced by muscle soluble factor(s)
J. Cell Biol.
Differential expression of two neuronal intermediate-filament proteins, peripherin and the low-molecular-mass neurofilament protein (NF-L), during the development of the rat
J. Neurosci.
Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation
Science
Functional circuitry in the brain of immune-challenged ratspartial involvement of protaglandins
J. Comp. Neurol.
Cited by (0)
- 1
Present address: Howard Hughes Medical Institute, Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA.
- 2
Present address: Department of Pathology, Harvard Medical School, Howard Hughes Medical Institute, 200 Longwood Avenue, Boston, MA 02115, USA.